2020
DOI: 10.1111/his.14059
|View full text |Cite
|
Sign up to set email alerts
|

Preservation of Epstein–Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer

Abstract: Aims: Epstein-Barr virus (EBV) in-situ hybridisation and mismatch repair (MMR) protein immunohistochemistry identifies two subgroups of gastric cancer (GC) with high immunogenicity and likelihood for response to immune check-point inhibition. As tumour biology may change during the metastatic course, which can negatively influence the success of therapeutic decisions made on primary tissue, we investigated the consistency of GC EBV and MMR status within primary tumours and metastases. Methods and results: We i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
15
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

4
4

Authors

Journals

citations
Cited by 15 publications
(18 citation statements)
references
References 21 publications
3
15
0
Order By: Relevance
“…EBV-associated tumors have been assigned a specific subtype only in the TCGA classification with a rate of 9%, but the majority of EBV-associated tumors group in the MSS/p53+ subtype of the ACRG (12/18 EBV positive tumors), and the authors admit that these tumors may represent an own subtype [15]. In our cohort, only two (1.7%) tumors are EBV-associated which is within the worldwide reported range of prevalence and in line with previous data of Switzerland [38,39]. The CIN subtype, with 50% being the most common subtype of TCGA classification, is characterized by chromosomal instability, namely the degree of aneuploidy and a high somatic copy number variation.…”
Section: Discussionsupporting
confidence: 91%
“…EBV-associated tumors have been assigned a specific subtype only in the TCGA classification with a rate of 9%, but the majority of EBV-associated tumors group in the MSS/p53+ subtype of the ACRG (12/18 EBV positive tumors), and the authors admit that these tumors may represent an own subtype [15]. In our cohort, only two (1.7%) tumors are EBV-associated which is within the worldwide reported range of prevalence and in line with previous data of Switzerland [38,39]. The CIN subtype, with 50% being the most common subtype of TCGA classification, is characterized by chromosomal instability, namely the degree of aneuploidy and a high somatic copy number variation.…”
Section: Discussionsupporting
confidence: 91%
“…In this retrospective, multicentre cohort study, we collected digitised histological slides from formalin-fixed paraffin-embedded gastric cancer resection samples with matched microsatellite instability and EBV status from ten cohorts of patients with gastric cancer. Samples from the ten cohorts were as follows: samples from the pathology archives of Inselspital, University of Bern (Bern, Switzerland—ie, the BERN cohort); 23 samples from the CLASSIC trial from participating study centres in South Korea (ie, the CLASSIC cohort); 24 samples from the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial from participating study centres in the UK (ie, the MAGIC cohort); 25 samples from the Leeds Teaching Hospitals National Health Service Trust (Leeds, UK—ie, the LEEDS cohort); samples from the Kanagawa Cancer Center Hospital (Yokohama, Japan—ie, the KCCH cohort); 26 samples from the pathology archive at the University Hospital Augsburg (Augsburg, Germany—ie, the AUGSB cohort); samples from the University of Siena (Siena, Italy—ie, the ITALIAN cohort); 27 samples from the pathology archive at University of Cologne (Cologne, Germany—ie, the KOELN cohort); 28 samples from the Institute of Pathology at the Technical University Munich (Munich, Germany—ie, the TUM cohort); 4 and samples (diagnostic slides) originate from the The Cancer Genome Atlas (TCGA) project and are derived from the National Institute of Health Genomic Data Commons portal ( the TCGA cohort ). 8 , 29 …”
Section: Methodsmentioning
confidence: 99%
“…All other data were provided by the respective study principal investigators and different data sharing policies apply as described previously in those original publications. We cannot make any individual patient-level data available to others, but these data can be requested from the respective pathology institutions as defined in the references for BERN, 23 CLASSIC, 24 MAGIC, 25 LEEDS, 26 KCCH, 26 AUGSB, 4 ITALIAN, 27 KOELN, 28 and TUM. 4 …”
Section: Data Sharingmentioning
confidence: 99%
“…In addition, we used four proprietary datasets: the DACHS study ("Darmkrebs: Chancen der Verhütung durch Screening"), a large population-based case-control and patient cohort study on CRC, including samples of patients with stages I-IV from different laboratories in southwestern Germany coordinated by the German Cancer Research Center (Heidelberg, Germany) [23,24]. The DACHS study was approved by the ethics committees of the University of Heidelberg and of the Medical Chambers of Baden-BERN dataset is a single-center dataset collected from clinical routine samples at the pathology archive at Inselspital, University of Bern (Bern, Switzerland) [25]. Use of this data set was approved by the local ethics commission, specifically granting the use of archival tissue for molecular and immunohistochemical analysis as well as tissue microarray construction (University of Bern, Switzerland, no.…”
Section: Ethics Statement and Patient Cohortsmentioning
confidence: 99%
“…The DACHS study was approved by the ethics committees of the University of Heidelberg and of the Medical Chambers of Baden-Württemberg and Rhineland-Palatinate, and all participants signed an informed consent. The BERN dataset is a single-center dataset collected from clinical routine samples at the pathology archive at Inselspital, University of Bern (Bern, Switzerland) [25]. Use of this data set was approved by the local ethics commission, specifically granting the use of archival tissue for molecular and immunohistochemical analysis as well as tissue microarray construction (University of Bern, Switzerland, no.…”
Section: Ethics Statement and Patient Cohortsmentioning
confidence: 99%